Intellia Therapeutics Inc is trading at $13.61, down 8.8% today, as the stock pulls back and consolidates following a sharp rally in the previous session.
- The stock surged 23.2% on June 15, 2026, after the company reported strong Phase 3 data for its hereditary angioedema therapy, lonvoguran ziclumeran (lonvo‑z).
- Today's downward movement is attributed to profit-taking by investors following the significant catalyst-driven price spike.